STOCK TITAN

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Editas Medicine, a prominent genome editing company, will host a conference call and webcast on May 4, 2022, at 8:00 a.m. ET to discuss its first-quarter 2022 results and provide a corporate update. U.S. participants can dial 877-407-0989, while international callers should use 201-389-0921, approximately five minutes before the call. A live webcast and replay will be available on the Editas Medicine website. The company specializes in developing CRISPR-based genomic medicines aimed at treating serious diseases globally.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of 2022.

To access the conference call:

  • U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.
  • Participants should ask to be connected to the Editas Medicine earnings conference call.

A live webcast and replay of the conference call can also be accessed in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com 

Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com 


FAQ

When is Editas Medicine's conference call for first quarter results?

Editas Medicine's conference call is scheduled for May 4, 2022, at 8:00 a.m. ET.

How can I access the Editas Medicine conference call?

To access the conference call, U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921.

Where can I find the webcast of Editas Medicine's earnings call?

The webcast of Editas Medicine's earnings call will be available in the Investors section of their website.

What is the focus of Editas Medicine?

Editas Medicine focuses on developing CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to create treatments for serious diseases.

What is the stock symbol for Editas Medicine?

The stock symbol for Editas Medicine is EDIT.

Editas Medicine, Inc.

NASDAQ:EDIT

EDIT Rankings

EDIT Latest News

EDIT Stock Data

110.61M
82.28M
0.32%
71.08%
19.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE